Loading...

David P Richman

TitlePROF-HCOMP
InstitutionUniversity of California Davis
DepartmentMED: NEUROLOGY
Address1515 Newton Ct
CA 95618
Phone530-754-5006
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Antigen-specific treatment of myasthenia gravis: Chimeric autoantibody receptor T cells targeting autoimmune B cells
    NIH/NINDS R21NS104516Jun 15, 2018 - May 31, 2020
    Role: Principal Investigator
    Development of Animal Models of Anti-MuSK Myasthenia
    NIH/NINDS R21NS071325Sep 30, 2010 - Aug 31, 2013
    Role: Principal Investigator
    IX INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS
    NIH/NINDS R13NS036137May 1, 1997 - Apr 30, 1998
    Role: Principal Investigator
    STRUCTURE/FUNCTION ANALYSIS OF ACCHR EPITOPES
    NIH/NINDS P01NS024304Jan 1, 1987 - Sep 30, 1992
    Role: Co-Principal Investigator
    PATHOGENIC MECHANISMS IN MYASTHENIA
    NIH/NINDS R01NS019779Jul 1, 1984 - Jun 30, 1997
    Role: Principal Investigator
    ANTIIDIOTYPIC ANTIBODIES IN MYASTHENIA
    NIH/NINDS R01NS015462Jul 1, 1979 - Mar 31, 1996
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dimachkie MM, Abuzinadah AR, Barohn RJ, Oskarsson B, Rocke DM, Dengel K, Richman D. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 Nov 08; 87(19):2067-2068. PMID: 27821567.
      View in: PubMed
    2. Richman D. Lipoprotein-like receptor 4 antibodies in myasthenia gravis: pathogenic or protective. Eur J Neurol. 2016 11; 23(11):1593-1594. PMID: 27753233.
      View in: PubMed
    3. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26; 87(4):419-25. PMID: 27358333; PMCID: PMC4977114.
    4. Oskarsson B, Rocke DM, Dengel K, Richman D. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 Mar 22; 86(12):1159-63. PMID: 26850977; PMCID: PMC4820129 [Available on 03/22/17].
    5. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman D, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8. PMID: 26662952.
      View in: PubMed
    6. Richman D. The Future of Research in Myasthenia. JAMA Neurol. 2015 Jul; 72(7):812-4. PMID: 26011044.
      View in: PubMed
    7. Ha JC, Richman D. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochim Biophys Acta. 2015 Apr; 1852(4):651-7. PMID: 25486268.
      View in: PubMed
    8. Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman D, Fairclough RH. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. Mol Immunol. 2014 Mar; 58(1):116-31. PMID: 24333757.
      View in: PubMed
    9. Kim SS, Richman D, Johnson WO, Hald JK, Agius MA. Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome. Mult Scler. 2014 Jan; 20(1):57-63. PMID: 23736535.
      View in: PubMed
    10. Richman D, Nishi K, Ferns MJ, Schnier J, Pytel P, Maselli RA, Agius MA. Animal models of antimuscle-specific kinase myasthenia. Ann N Y Acad Sci. 2012 Dec; 1274:140-7. PMID: 23252909; PMCID: PMC3915870.
    11. Richman D, Yu Y, Lee TT, Tseng PY, Yu WP, Maselli RA, Tang CY, Chen TY. Dominantly inherited myotonia congenita resulting from a mutation that increases open probability of the muscle chloride channel CLC-1. Neuromolecular Med. 2012 Dec; 14(4):328-37. PMID: 22790975; PMCID: PMC3508202.
    12. Kim JY, Park KD, Richman D. Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol. 2011 Dec; 7(4):173-83. PMID: 22259613; PMCID: PMC3259491.
    13. Richman D. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. Arch Neurol. 2012 Apr; 69(4):434-5. PMID: 22158717; PMCID: PMC3903387.
    14. Richman D, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol. 2012 Apr; 69(4):453-60. PMID: 22158720; PMCID: PMC3915865.
    15. Kim SS, Richman D, Zamvil SS, Agius MA. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J Neurol Sci. 2011 Jul 15; 306(1-2):9-15. PMID: 21529843; PMCID: PMC4172440.
    16. Wong VS, Adamczyk P, Dahlin B, Richman D, Wheelock V. Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions. Cogn Behav Neurol. 2011 Mar; 24(1):40-2. PMID: 21467920.
      View in: PubMed
    17. Anderson JA, Ng JJ, Bowe C, McDonald C, Richman D, Wollmann RL, Maselli RA. Variable phenotypes associated with mutations in DOK7. Muscle Nerve. 2008 Apr; 37(4):448-56. PMID: 18161030.
      View in: PubMed
    18. Richman D, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003 Dec 23; 61(12):1652-61. PMID: 14694025.
      View in: PubMed
    19. Richman D, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci. 2003 Sep; 998:457-72. PMID: 14592915.
      View in: PubMed
    20. Agius MA, Richman D, Fairclough RH, Aarli J, Gilhus NE, Romi F. Three forms of immune myasthenia. Ann N Y Acad Sci. 2003 Sep; 998:453-6. PMID: 14592914.
      View in: PubMed
    21. Fairclough RH, Agius MA, Gudipati E, Silvian L, Hamaoka B, Beltzner CC, Lin MY, Chuang AR, Richman D. Agonist-induced transitions of the acetylcholine receptor. Ann N Y Acad Sci. 2003 Sep; 998:101-13. PMID: 14592867.
      View in: PubMed